Patients who receive avacopan for antineutrophil cytoplasmic antibody-associated vasculitis demonstrate fewer infections and ...

Objectives We evaluated the feasibility of a rapid glucocorticoid tapering regimen to reduce glucocorticoid exposure in patients with giant cell arteritis (GCA) treated with glucocorticoids ...

“While the phase 3 results of GCAptAIN did not replicate the positive outcomes observed in the phase 2 trial, we remain committed to continuing to drive scientific progress and deepening the ...

Upadacitinib 15 mg — but not 7.5 mg — alongside a glucocorticoid taper demonstrated superior efficacy to placebo with a ...

"Novartis’ Cosentyx shows no benefit in Phase III GCA trial" was originally created and published by Clinical Trials Arena, a ...

A common medication already used for autoimmune diseases such as rheumatoid arthritis is effective for patients with giant cell arteritis, according to findings from a team at the Perelman School of ...

Causing the body’s immune system to attack blood vessels in the head, neck, and other areas, giant cell arteritis often leads to headaches, vision loss, and even aortic aneurysms.

So recognizing GCA early, treating it aggressively and planning wisely, that’s how we can preserve site function and quality of life. Thank you very much. Giant cell arteritis or GCA is an autoimmune ...

Granuloma Formation to Neutralize Antigen Mature and activated DCs present antigen to CD4 + T cells in the adventitia, leading to T-cell activation and proliferation. These activated T cells ...

Abstract Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are linked conditions that occur in the elderly. GCA is a vasculitis of large- and medium-sized vessels causing critical ischemia.